英文名 | N-Formyl-methionyl-leucyl-phenylalanine | CAS號 | 59880-97-6 |
產品編號 | FS1419 | 分子式 | C21H31N3O5S |
產品分類 | 化合物與抑制劑 | 分子量 | 437.5529 |
純度 | ≥98% | 儲存條件 | -20℃ |
產品簡介
N-甲酰-蛋氨酸-亮氨酸-苯丙氨酸(N-Formyl-Met-Leu-Phe, fMLP),一種有效的內源性趨化肽,是甲酰化肽受體1(FPR1)(Ki=38nM)的激動劑。fMLP活化甲酰化肽受體(FPRs)引起細胞活化,典型特征有細胞極化、趨化性和蛋白水解酶的釋放。fMLP是吞噬性白細胞的化學引誘物。刺激隨機和定向移動。是超氧化物釋放的誘導劑。fMLP誘導分離豚鼠空腸(EC50 = 11 nM)、近端結腸(EC50 = 3.5 nM)和遠端結腸(EC50 = 2.2 nM)的收縮。體外,fMLP誘發腸運動神經元神經遞質的釋放。
產品特性
CAS :59880-97-6
化學名:N-formyl-L-methionyl-L-leucyl-L-phenylalanine
同義名:fMLF; fMLP; N-Formyl-MLF; NSC 350593;
分子式:C21H31N3O5S
分子量:437.6 g/mol
純度:≥98%
外觀:固體
溶解性:溶于DMSO(30mg/ml)、DMF(25mg/ml)、乙醇(0.5mg/ml),幾乎不溶于水
單字母序列:Formyl-MLF
三字母序列:Formyl-Met-Leu-Phe
保存與運輸方法:-20℃干燥保存,至少1年有效。 冰袋運輸。
【注】:請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。儲備液置于-80°C保存,約6個月有效;-20°C保存,約1個月有效。
【注】:建議用無氧水來配制稀釋fMLP儲存液的緩沖液(比如:PBS,生理鹽水),由于蛋氨酸對氧敏感。稀釋后的工作液現配現用。
儲存液制備
質量
溶劑體積 濃度 |
5mg | 25mg | 50mg |
1mM | 11.4260 mL | 57.1298 mL | 114.2596 mL |
5mM | 2.2852 mL | 11.4260 mL | 22.8519 mL |
10mM | 1.1426 mL | 5.7130 mL | 11.4260 mL |
【溫馨提示①】:請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。儲備液置于-80°C保存,約6個月有效;-20°C保存,約1個月有效。
【溫馨提示②】:建議用無氧水來配制稀釋fMLP儲存液的緩沖液(比如:PBS,生理鹽水),由于蛋氨酸對氧敏感。稀釋后的工作液現配現用。
使用方法【源自文獻,僅作參考】
文獻1,Hamilton JL, Mohamed MF, Witt BR, Wimmer MA, Shafikhani SH. Therapeutic assessment of N-formyl-methionyl-leucyl-phenylalanine (fMLP) in reducing periprosthetic joint infection. Eur Cell Mater. 2021;42:122-138. Published 2021 Aug 26. doi:10.22203/eCM.v042a
體內研究(動物模型): 動物模型(Animal Model):12-week-old C57BL/6J mice 配制方法(Formulation):fMLP was prepared at a concentration of 1 μg/μL in a solution of 25 % DMSO and 75 % PBS. Vehicle control was a 5 μL solution of 25 % DMSO and 75 % PBS. 實驗方法(Assay):12-week-old C57BL/6J mice received local intra-articular injection of fMLP or vehicle control at the right-knee joint. Mice were anaesthetised using 2 % isoflurane. A total of 5 μL of fMLP solution or vehicle control was injected into the right hindlimb knee joint using a 5 μL Hamilton® syringe and 27-Gauge needle, as previously described. The dosing of 5 μg of fMLP was chosen based on its maximum solubility in vehicle solution and maximum volume of solution that could be injected into the knee-joint space. |
文獻2,Zhu L, He P. fMLP-stimulated release of reactive oxygen species from adherent leukocytes increases microvessel permeability. Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H365-72. doi: 10.1152/ ajpheart.00812.2005. Epub 2005 Sep 9. PMID: 16155097.
體外研究(細胞水平): 細胞類型(Cell Type):Rat neutrophils 配制方法(Formulation):The stock solution of fMLP (10 mM) was prepared with 100% DMSO, and the final concentration (10 μM) was achieved by 1:1,000 dilution with albumin-Ringer solution. 實驗方法(Assay):Neutrophils were preincubated at 37°C for 10 min before the CL measurement. Each sample (0.25 ml) contained 0.5 × 106 neutrophils with 0.8 μM luminol. The reaction to fMLP (10 μM final concentration) or TNF-α (5 ng/ml final concentrations) was initiated by automated injection to ensure an immediate mixing and measurement. |
注意事項
1) 關于化合物溶解性:產品特性內的“≥”表明溶于標示濃度,但飽和溶解度未知。不同批次化合物的溶解度會有差異。
2) 為了讓化合物更好的溶解,可通過37℃加熱或(和)超聲波水浴中震動片刻來處理。若實驗所需濃度過大甚至達產品溶解極限,請添加助溶劑助溶或自行調整濃度。
3) 為了您的安全和健康,請穿實驗服并戴一次性手套操作。